Introduction
Niacin's potent lipid-modifying properties were first described in normal and hypercholesterolemic patients in 1955 by Altschul et al. [1] . Niacin favorably modulates the lipoprotein profile by reducing total cholesterol, low-density lipoprotein cholesterol (LDL-C), and triglycerides (TG) and raising high-density lipoprotein cholesterol (HDL-C) [2] . Niacin is one of the few drugs that also significantly lowers lipoprotein (a) [Lp(a)] [3] , identified as an independent risk factor for cardiovascular disease (CVD) [4, 5] . In the prestatin era, niacin was the first pharmacologic agent that reduced the incidence of nonfatal myocardial infarction and cardiac death [6, 7] . Niacin has also shown beneficial effects on arterial plaque regression in combination with statin therapy [8, 9] . However, in recent clinical outcomes trials, including The Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglycerides and Impact on Global Health Outcomes (AIM-HIGH) trial, the addition of extendedrelease (ER) niacin to intensive LDL-C-lowering therapy did not reduce atherothrombotic events compared with LDL-C-lowering therapy alone [10, 11] .
The pharmacological effects of niacin are not well understood. Most prominently, niacin stimulates the hydroxyl-carboxylic acid receptor 2 (HCAR2; also known as GPR109A and the niacin receptor) located on the surface of adipocytes, resulting in the antilipolytic effect of the drug [12] . The reduction in free fatty acids returning to the liver may reduce the assembly and secretion of very low density lipoprotein cholesterol [2] ; however, additional mechanisms may be operative [13] . As HCAR2 is not expressed in the liver, in-vitro studies suggest that niacin may inhibit TG synthesis by directly inhibiting diacylglyercol acyltransferase-2, the key enzyme for TG synthesis [14] . Niacin may increase HDL-C by reduction of HDL-apoA-I catabolism [15] and inhibition of cholesteryl ester transfer protein [16] . The mechanism of Lp(a)-lowering with niacin is unknown.
There is a growing body of literature regarding additional anti-inflammatory effects of niacin that are both dependent on [17] [18] [19] [20] and independent [21] of HCAR2. This receptor is expressed in various immune cells of the body such as macrophages, neutrophils, and epidermal Langerhans cells [17, 18] . In an experimental model of mice deficient in HCAR2, Lukasova et al. [17] showed that niacin reduced the progression of atherosclerosis by a HCAR2-mediated effect on bone-marrow derived cells, independent of its lipid-lowering effect.
The effects of niacin on lipids and cardiovascular (CV) risk are variable. Genetic variation in HCAR2 could influence the effects of niacin on plasma lipids, Lp(a), or CV events, but this has not been tested [22] . First, we sequenced HCAR2 in 294 healthy individuals to discover novel coding variants. We identified two commonly occurring coding single-nucleotide polymorphisms (SNPs): rs7314976 (C931T, p.R311C) and rs2454727 (G951A, p.M317I), occurring in the C-terminal tail. However, the functionality of these SNPs is unknown. The primary aim of this study was to determine whether these variants were associated with the change in LDL-C, HDL-C, TG, and Lp(a) following treatment with ER niacin in the AIM-HIGH study. The secondary aim was to determine whether the HCAR2 variants were associated with CV events in the trial and differentially modulated by treatment group.
Participants and methods

Ethics statement
AIM-HIGH participants provided written informed consent and all research was carried out according to the principles outlined in the Declaration of Helsinki. The protocol was approved by the Institutional Review Boards (IRB) at all participating clinical sites. The genetic sub-study of AIM-HIGH was approved by the IRB at the University of Pennsylvania.
Healthy cohort study
This preliminary study recruited healthy volunteers to a University of Pennsylvania inpatient Clinical and Translational Research Center protocol to investigate the genomic basis of the flushing and metabolic responses to pharmacological doses of niacin. Healthy men and nonpregnant, nonlactating women 18-45 years of age, with BMI 18-30 kg/m 2 , and of self-reported White or Black race were included. Here, we report the results of the HCAR2 gene sequencing in 294 individuals. The study was approved by the University of Pennsylvania Institutional Review Board (NCT00953667). All participants provided written informed consent.
AIM-HIGH cohort
The AIM-HIGH study (NCT00120289) design and baseline characteristics of the participants have been published previously [10] . Briefly, the trial tested whether ER niacin 1500-2000 mg/day added to intensive statin therapy, compared with statin therapy alone, would reduce the risk of CV events in patients with established atherosclerotic CVD and atherogenic dyslipidemia (low levels of HDL-C, elevated TG, and small dense particles of LDL-C). Of the total 3414 AIM-HIGH participants randomized to the trial, 2067 had provided DNA and had complete phenotype data that enabled the current analysis.
Laboratory methods
Analytical measurements
Lipid and Lp(a) measurements were performed at the Northwest Lipid Metabolism and Diabetes Research Laboratory at the University of Washington as described previously [10] . Analysis of Lp(a) was carried out by a monoclonal antibody-based enzyme-linked immunoadsorbent assay as published previously [23] .
Sequencing of HCAR2 in the healthy cohort study DNA was extracted from buffy coat samples using a QIA Symphony SP instrument (Qiagen Inc., Valencia, California, USA). Because of the high degree of homology of HCAR2 and HCAR3, being 95% identical at the protein level [24] , we used a two-step process for sequencing using a nested primer approach. We sequenced the 5′-untranslated region and the coding sequence (Fig. 1) . PCR amplification and sequencing of the single exon region of HCAR2 were carried out with the following primers for amplification: forward: ACATGACA TAAAGGCAGGCGT; reverse: TTCTTGCGATGGTTA TTTAAGGAG. PCR reactions were amplified in a total volume of 25 μl using 100 ng of genomic DNA, 0.4 µmol/l of each forward and reverse primer, and ready-to-go PCR beads (Amersham; GE Healthcare Life Sciences, Pittsburgh, Pennsylvania, USA ) under denaturation at 94°C for 2 min, followed by 35 cycles (94°C for 30 s, 62°C for 30 s, and 72°C for 90 s) and an extension at 72°C for 7 min. The unincorporated nucleotides and primers were removed by incubation with ExoSAP-IT (USB Corp., Cleveland, Ohio, USA) for 15 min at 37°C, followed by enzyme inactivation at 80°C for 15 min before sequencing. Sequencing was performed at GENEWIZ Inc. (South Plainfield, New Jersey, USA) with the following primers: forward: GATGCCGATCCAGA ATGGCGG; forward: CACCACACAGACACACACCT CC; reverse: CCGCCATTCTGGATCGGCATC; reverse: TTCTTGCGATGGTTATTTAAGGA. Sequences were aligned using Sequencher software (GeneCodes Corp., Ann Arbor, Michigan, USA). Allelic variations noted from multiple alignments were verified by inspecting chromatograms.
Linkage disequilibrium blocks in each race group were identified using Haploview 4.2 [25] .
Genotyping in AIM-HIGH DNA was extracted from buffy coat samples using the FlexiGene DNA Kit (Qiagen Inc.). We used a two-step process for genotyping using a nested primer approach. First, we amplified the HCAR2 gene region with the primers described above. SNPs in HCAR2, rs7314976 and rs2454727, were genotyped in AIM-HIGH participants using the TaqMan Allelic discrimination Assay (Applied Biosystems, Foster City, California, USA). Participants were excluded from the analysis if they reported race other than White or Black (n = 27). The HCAR2 p.R311C and p.M317I variants were genotyped successfully in 2050 and 2067 individuals, respectively. The TaqMan genotyping call rate was 96%, with an error rate of 8% for p.R311C and 6% for p.M317I as determined on 51 DNA samples genotyped in duplicate. In all cases, discordant calls were caused on the pair being classified as a genotype call and the other member of the pair being classified as failure to genotype. All SNPS were consistent with Hardy-Weinberg equilibrium (P > 0.2). Participants were excluded from the analysis if they were missing outcome data, leaving 1994 White and 73 Black individuals for the baseline lipoprotein analysis and 1818 White and 58 Black individuals for the 1-year lipoprotein analysis. The CV event analysis was carried out in 1994 White and 73 Black individuals for whom event data were available.
Statistical analysis
The primary outcomes were defined as the percent change in the plasma concentrations of LDL-C, HDL-C, TG, and Lp(a) from baseline to 1 year after treatment with either statin + placebo or statin + ER niacin. Secondarily, we also examined the baseline pretreatment plasma concentrations of the lipid traits. Baseline TG and Lp(a) were log-transformed before analysis because of a non-normal distribution. The percent changes in lipids and Lp(a) at 1 year were normally distributed. We carried out a linear regression analysis to test the dominant effect [26] of the HCAR2 genotype on baseline lipid and Lp(a) values and on the percent change in lipids and Lp(a) at 1 year after randomization, adjusting for age, sex, BMI, and baseline lipid values. The 1-year lipid and Lp(a) outcomes were evaluated separately in the niacin and placebo groups. The analyses were first carried out separately for each race group to avoid population stratification. As there was no race x treatment interaction in the percent change in lipid and Lp(a), we also reported the combined results. Cox regression models were fit to determine the hazard of experiencing a CV event including the HCAR2 genotype, age, sex, race, and BMI in the model. Kaplan-Meier survival curves for time to CV event were created for the HCAR2 M317I variant. CV events were defined as the composite of death from coronary heart disease, nonfatal myocardial infarction, ischemic stroke, hospitalization for an acute coronary syndrome, or symptom-driven coronary or cerebral revascularization [10] . For the primary outcome, the Bonferroni correction was applied to account for multiple comparisons, on the basis of eight tests (2 SNPs × 4 lipid traits), so that each association was claimed at the level of 0.006. A post-hoc power analysis was carried out for the change in Lp(a) outcome in the niacin group. With 916 patients, we had 74% power to detect the differences in the means that we observed by the M317I genotype at an alpha level of 0.006. Analysis was carried out using STATA version 13.1 (StataCorp., College Station, Texas, USA).
Results
We sequenced the single exon HCAR2 gene in 294 healthy individuals. The summary of the variation is listed in Table 1 . Figure 1 provides a schematic of the HCAR2 gene structure and the location of the SNPs identified by the sequencing study. Six polymorphic sites were identified; two of these resulted in amino acid changes. The two most common coding variants C931T (p.R311C) and G951A (p.M317I) occurred at a lower frequency in the Black participants (Table 1) . These variants were predicted to be benign by SIFT and PolyPhen [27] . The coding variants were in linkage disequilibrium (r 2 = 0.96 for Whites and r 2 = 1.0 for Blacks). One major linkage disequilibrium block was identified in 
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Schematic of the HCAR2 gene structure. The 5′-untranslated region (UTR) and all 1092 nucleotides of the coding region were sequenced in healthy individuals. The location of nonsynonymous single-nucleotide polymorphisms (SNPs) identified in this study is denoted by diamonds, whereas the synonymous SNPs are denoted by the triangles. The transmembrane domains of the translated protein are depicted by dark gray boxes.
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each race group ( Supplementary Fig. S1 , Supplemental digital content 1, http://links.lww.com/FPC/B220). To determine whether variation in HCAR2 was associated with the lipid response to niacin, we chose to genotype these two commonly occurring coding SNPs in the AIM-HIGH cohort.
The clinical and demographic characteristics for the AIM-HIGH population that provided DNA during the course of the study (n = 2067) compared with the entire cohort are provided in Table 2 . There was no difference between baseline lipid values found in the genetic subgroup compared with the larger AIM-HIGH study cohort [10, 23] . In the complete cohort, as published previously, the addition of ER niacin to statin treatment resulted in a 25% increase in HDL-C compared with 10% in the placebo group at 2 years (P < 0.001). Niacin further decreased LDL-C by 12.0% and TG concentrations by 28.6% compared with 5.5 and 8.1% in the placebo group, respectively [10] . In a separate analysis of AIM-HIGH, niacin significantly decreased the Lp(a) levels by 21% in the statin + ER niacin group compared with 5.9% in the statin + placebo group (P < 0.05) [23] . Table 3 We then tested whether each SNP was associated with the change in lipids from baseline to 1 year after randomization. The percent changes in LDL-C, HDL-C, and TG were not associated significantly with HCAR2 variants in individuals of either White (Table 4) or Black (Table 5) ancestry. Interestingly, the mean reduction in Lp(a) in response to niacin was significantly greater in homozygous carriers of the 317M major allele (− 22.7 35%; P = 0.005) than in carriers of the minor allele (− 15.3 39.4%) ( Table 4 and Fig. 2 ). This was directionally consistent in the small number of Black participants (Table 5) , and upon combining both race groups the robust response of Lp(a) to niacin in the 317M homozygous major allele carriers was statistically significant (P = 0.003). In addition, the reduction in Lp(a) and the 317M genotype was evaluated in an interaction model and there was a significant treatment × genotype effect (P interaction = 0.005). The Lp(a)-lowering effect because of niacin did not follow an additive model as a similar decrease was observed in 317I minor allele carriers. There were minimal changes in Lp(a) in the placebo group and no differences by the HCAR2 genotype (Tables 4 and 5 ).
We then tested whether the CV event rate was different by the HCAR2 genotype by Cox regression modeling. Table 1 Summary SIFT and PolyPhen scores obtained from http://www.ensembl.org; both of these variants were predicted to be tolerated by SIFT and benign by PolyPhen. Table 2 Clinical and demographic characteristics of the AIM-HIGH participants a HDL-C levels were nominally lower in the statin + extended-release niacin group at baseline P = 0.04 in the genetic subgroup and in the entire AIM-HIGH cohort as reported previously.
The HCAR2 genotype did not increase the hazard of a CV event in either the placebo or the niacin group (Table 6 , Supplementary Fig. S2 , Supplemental digital content 2, http://links.lww.com/FPC/B221).
Discussion
In this study, we evaluated whether two coding variants in HCAR2 (p.R311C and p.M317I) were associated with lipid and Lp(a) response to niacin in the AIM-HIGH trial. Polymorphisms in HCAR2 did not predict the change in LDL-C, HDL-C, or TG after 1 year of niacin therapy. The reduction in Lp(a) in response to niacin was significantly greater in the homozygous carriers of the 317M major allele compared with minor allele carriers. Our findings confirm a previous report suggesting that niacin's lipid effect is independent of the HCAR2 receptor [13] . However, this is the first study to suggest that activation of the HCAR2 receptor by niacin may mediate Lp(a) lowering. Neither HCAR2 variant was associated with CV events in our analysis. This study is the first large association study of these variants and the first pharmacogenetic study of niacin therapy.
The functionality of the p.R311C and p.M317I variants in HCAR2 is not well known. The first SNP results in an arginine to cysteine substitution at amino acid 311 and the latter SNP results in a methionine to isoleucine substitution at amino acid 317. Prediction tools [27] to identify pathogenic variants such as Polyphen and SIFT have categorized these variants as benign. However, these tools rely heavily on sequence conservations among Table 3 Association of HCAR2 variants with baseline lipid values in participants from the AIM-HIGH study Cys-Cys (n = 0) P-value Lipid traits reported as mean + / -SD; percent change from baseline to 1 year. HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; Lp(a), lipoprotein (a); SNP, single-nucleotide polymorphism; TG, triglycerides. P values were calculated from a dominant model adjusting for age, sex, BMI, and baseline lipid levels.
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species and may not result in reliable predictions for variants located in a residue that is not present in the majority of species, as is the case for HCAR2. In addition, many functional prediction tools do not account for the location of the variants, which may have a major impact if they occur in a critical region of the protein or are involved with protein-protein interactions [27] . The p.R311C and p.M317I variants are not located in the transmembrane regions of the receptor and therefore are not involved with niacin binding [28] . Rather, they are found in the C-terminal tail, which has been shown to be functionally important for facilitating the interactions with various cellular proteins regulating receptor desensitization and endocytosis in several GPCR family members [29] . In-vitro experiments involving mutations of structural motifs in the C-terminal region of HCAR2 found that this region plays an important role in the regulation of the receptor surface localization and specifically the Δ315-328 mutant, the region of the M317I variant, showed a significant decrease in niacin-mediated internalization and arrestin3 translocation [30] . Although mutagenesis experiments for the specific coding variants that we describe have not been published in the peer-reviewed literature, patent literature from Arena Pharmaceuticals has shown that the 317I variant results in reduced ERK 1/2 phosphorylation and mitogenactivated protein kinase activation in cell-based assays [31] . If this is the case, individuals with this polymorphism would be expected to have reduced ERK 1/2 phosphorylation in response to niacin therapy.
Lp(a) is an atherogenic particle that has been associated with an increased risk of coronary disease and stroke [4, 5] . Lp(a) consists of an LDL-like particle bound to a plasminogen-like glycoprotein, apolipoprotein (a) [32] . Lp(a) levels are highly genetically influenced, with copynumber variation within the kringle IV -type 2 repeat of apolipoprotein (a) explaining 40% of the variation [33] . The numbers of kringle IV-2 repeats are inversely correlated with Lp(a) levels [33] . The contribution of Lp(a) toward CVD risk is not well understood, but because of its structural composition, it may contribute toward both atherosclerosis and thrombosis [32] .
In this study, we found significantly greater reduction in Lp(a) in response to niacin in homozygous carriers of the 317M major allele compared with carriers of the minor allele. It is unknown how signaling through the HCAR2 receptor may influence plasma Lp(a) concentrations. Lp(a) is found in atherosclerotic plaques and involved in macrophage foam cell formation similar to LDL [32] . The HCAR2 receptor is also found on macrophage and niacin, acting through HCAR2, has been shown to Table 5 Association of HCAR2 variants with percent change in lipid values at 1 year by treatment in the Black participants Statin + placebo Statin + extended-release niacin SNP Trait Arg-Arg (n = 26) Arg-Cys (n = 1) Cys-Cys (n = 0) P-value Arg-Arg (n = 25) Arg-Cys (n = 6) Cys-Cys (n = 0) P-value Change in lipoprotein (a) levels by the HCAR2 (rs2454727) genotype in White participants from the AIM-HIGH trial. The reduction in Lp(a) in response to niacin was greater in homozygous 317M carriers compared with 317I carriers (P = 0.0053 in the niacin group; P = 0.37 in the placebo group; P interaction = 0.005). The boxes on the boxplots represent the 75th percentile, median, and 25th percentile.
stimulate cholesterol efflux by increasing ABCA1, ABCG1, and CD36 expression [17, 34, 35] . Carriers of the major allele may have enhanced ability to efflux lipid from foam cells. Alternatively, niacin may also work to lower Lp(a) through anti-inflammatory mechanisms. Lp (a), through its apo(a) component, has be shown to promote oxidative and inflammatory actions on the vascular wall [32, 36] . The apo(a) domain was found to increase IL-8 mRNA and protein expression in macrophage by the oxidized phospholipid modification of Lp(a) that facilitated the interaction of Lp(a) with CD36 and macrophage toll-like receptor [37] . Niacin also exerts antiinflammatory effects that have been shown to be dependent on HCAR2 receptor activation on immune cells including macrophages, monocytes, neutrophils, and dermal dendritic cells [17, 20, 38, 39] . Niacin activation of HCAR2 inhibited monocyte chemotactic protein-1-induced macrophage recruitment into atherosclerotic plaques; this effect was abolished in HCAR2-deficient mice [17] . Chemokine signaling through monocyte chemotactic protein-1 is a key component of immune cell recruitment into the atherosclerotic vessel wall and niacin may reduce atherosclerosis by interfering with intracellular signaling pathways induced through chemokine receptors, which are also mediated through Gi-type G-proteins [17, 40] . As the HCAR2 317I variant causes reduced intracellular signaling as shown by decreased ERK 1/2 phosphorylation and mitogen-activated protein kinase activation, it is conceivable that this variant cannot activate the necessary signaling pathways to interfere with macrophage chemotaxis and therefore would show a reduced antiinflammatory and antiatherosclerotic response when exposed to niacin. However, we could not find a difference in CV events rates by the HCAR2 genotype, likely because of the low number of events in the overall trial.
Although we performed the genetic evaluation within the context of a prospective, randomized placebo-controlled design with longitudinal follow-up of lipids and CV events, this study has several limitations. We did not have access to another cohort of chronic niacin treatment to replicate our findings; thus, our findings would require replication. It would be worth investigating whether these findings could be replicated in the HPS2-THRIVE study that used a similar trial design [11] . The overall number of CV events was low in this study, limiting our ability to evaluate the effect of HCAR2 variants on these outcomes. The two coding variants that we investigated are not found on genome-wide arrays, likely because of 95% sequence homology of HCAR2 with HCAR3 [24] , and therefore have not been associated with lipid traits in previous genome-wide association studies [41, 42] . We used a two-step process to successfully amplify the SNP region, and this added step may limit high-throughput genotyping in larger cohorts. Despite high homology to HCAR2, HCAR3 has ∼1000-fold less affinity for nicotinic acid and has been identified as a receptor for 3-OHoctanoic acid [43, 44] . Further work is required to clarify the role of Lp(a) levels as a contributor toward CV risk in the Black population. It is known that Blacks have higher Lp(a) levels than the White population, [45] but these higher levels have not been consistently shown to translate into a higher risk of CV events in Blacks [46, 47] . Consensus statements from the European Atherosclerosis Society state that individuals are at increased risk for CVD at levels more than 30 mg/dl (approximately equivalent to 75 mmol/l by newer assays) [48] , but these cut-points may not apply to individuals of Black or Asian ancestry [49] . We also observed higher Lp(a) levels at baseline in the AIM-HIGH trial, but the greatest benefit in terms of Lp(a) lowering because of niacin was observed in homozygous carriers of the 317M allele in both race groups. It is still unclear from the literature as to what is the optimal level of Lp(a) reduction required in Black individuals to achieve CV risk reduction.
Conclusion
We observed differential Lp(a) lowering on the basis of genotype at the M317I variant in response to niacin. We did not find an association, however, between coding variants in HCAR2 and the change in plasma LDL-C, HDL-C, or TG with niacin treatment. Understanding the genetic contribution toward variation in response to niacin therapy, including Lp(a) reduction, could uncover mechanisms by which niacin decreases Lp(a), an important independent risk factor for CVD. Research Program grant from the American Heart Association (11CRP7610016). AIM-HIGH was supported by the National Heart, Lung, and Blood Institute (U01 HL081616 and U01 HL081649) and by an unrestricted grant from AbbVie Inc. AbbVie donated the extendedrelease niacin, the matching placebo, and the ezetimibe; Merck donated the simvastatin.
